TG Therapeutics, Inc. Forecast, price target & analysts
TG Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
TG Therapeutics, Inc. Classifications & Recommendation
TG Therapeutics, Inc. Price Target
| Target Price | $78.03 |
| Price | $53.91 |
| Potential |
44.74%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target TG Therapeutics, Inc. 2027 .
The average TG Therapeutics, Inc. target price is $78.03.
This is
44.74%
register free of charge
$90.30
67.50%
register free of charge
$21.21
60.66%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend TG Therapeutics, Inc. to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the TG Therapeutics, Inc. stock has an average upside potential 2027 of
44.74%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 616.29 | 979.41 |
| 87.32% | 58.92% | |
| EBITDA Margin | 20.02% | 23.48% |
| 56.82% | 17.28% | |
| Net Margin | 72.56% | 15.53% |
| 921.05% | 78.60% |
9 Analysts have issued a sales forecast TG Therapeutics, Inc. 2026 . The average TG Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an TG Therapeutics, Inc. EBITDA forecast 2026. The average TG Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 TG Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average TG Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.77 | 0.99 |
| 1,746.67% | 64.26% | |
| P/E | 54.63 | |
| EV/Sales | 8.68 |
9 Analysts have issued a TG Therapeutics, Inc. forecast for earnings per share. The average TG Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
TG Therapeutics, Inc....
Current TG Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jul 07 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 06 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Jul 27 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jul 07 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 06 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 27 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
